U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314294) titled 'Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients' on Dec. 04, 2025.
Brief Summary: This study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments. Patients will be randomly assigned to one of two dosing schedules: EMB-01 once weekly, or once weekly for 6 weeks then every two weeks.
Study Start Date: Dec. 30, 2025
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Cancer
Intervention:
DRUG: EMB-01 1600 mg administered once weekly throughout the study
Participants receive EMB-01 at a dose o...